Pfizer's Oncology Research Unit (ORU) strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. The ORU comprises four pillars: Tumor Cell Biology; Bioconjugates Discovery and Development; Precision Medicine; and Integrative Biology and Biochemistry. The Tumor Cell Biology group is focused on oncogenic drivers and emerging biology. The ORU seeks to establish industry leadership in bioconjugates with a focus on Antibody Drug Conjugates (ADCs). Precision Medicine represents an integrated cluster of technology platforms and translational science to enable patient-tailored, hypothesis-driven experimental medicine approaches. Finally, our Integrative Biology and Biochemistry team supports novel target identification and validation through functional genomics, proteomics, and other "omic" approaches.

WRD is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

  • Lung, colorectal, breast, ovarian, prostate, pancreatic, and hematologic cancers
  • Cancers prevalent in Asia (e.g., gastric cancer, hepatocellular carcinoma)

Specific areas of interest include:

  • Targets and technologies that enable antibody and ADC approaches
  • Oncogenic signaling mechanisms
  • Tumor metabolism
  • Epigenetics
  • Directed tumor cell killing via immune-based mechanisms
  • Precision medicine
  • Peptide and bioconjugation technologies and analysis
  • Functional genomics

Not actively seeking partnering opportunities in:

  • Gene therapies
  • Antisense / siRNA / shRNA therapeutics
  • Systemic immune modulation
  • Reformulated cytotoxic agents
  • Radioconjugates
  • Oncolytic Viruses

By clicking the following link, you'll go back to Biotherapeutics Oncology section.

R & D Brochure


Understand what R&D is looking for in an early stage opportunity.


Connect With Us


Reach out. We want to hear from you.